Jul 13, 2022

Verve starts first human test of gene editing treatment for heart disease

Posted by in categories: bioengineering, biotech/medical

A patient in New Zealand became the first person to receive the biotech’s medicine, which uses base editing to turn off a specific gene in the liver and thereby lower cholesterol.

Comments are closed.